53.71 +0.06 (0.11%)
After hours: 4:38PM EDT
|Bid||53.00 x 800|
|Ask||53.73 x 1800|
|Day's range||53.51 - 54.49|
|52-week range||49.96 - 70.05|
|PE ratio (TTM)||95.63|
|Earnings date||26 Jul 2018|
|Forward dividend & yield||1.60 (2.92%)|
|1y target est||57.32|
Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.
Bristol-Myers Squibb Company today announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti to pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma , achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for patients treated with EPd ...
PRINCETON, N.J.--(BUSINESSWIRE)-- Primary endpoint of progression-free survival met for the combination of Empliciti plus pomalidomide and low-dose dexamethasone Data will be presented for the first time ...
Bristol-Myers Squibb Company announced today that the China National Drug Administration has approved Opdivo for the treatment of locally advanced or metastatic non-small cell lung cancer after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations.
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty cents per share on the $.10 par value Common Stock of the corporation.
Bristol-Myers Squibb Company today confirmed that 31 abstracts demonstrating The Company’s immunoscience-research focus as well as how ORENCIA® therapy may impact diverse patient subgroups will be presented at the Annual European Congress of Rheumatology , June 13-16 in Amsterdam.
Bristol-Myers Squibb Company (NYSE:BMY) is currently trading at a trailing P/E of 94.7x, which is higher than the industry average of 23.7x. Although some investors may jump to the conclusionRead More...
Bristol-Myers Squibb Company will take part in Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018, in Rancho Palos Verdes, CA. Johanna Mercier, Head of U.S.
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.
Bristol-Myers Squibb Company will announce results for the second quarter of 2018 on Thursday, July 26, 2018. During a conference call at 10:30 a.m. EDT on July 26, company executives will review financial information and will address inquiries from investors and analysts.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.
The latest results from a collaboration testing Bristol-Myers Squibb’s cancer drug Opdivo with Nektar Therapeutics’ NKTR-214 didn’t exactly impress investors. Wall Street analysts described the phase 1/2 clinical trial data as “underwhelming” and “immature,” and Nektar (NKTR) shares plummeted 41.8 on Monday. Combination treatments that pair two cancer drugs in an effort to boost their effect are an important trend in cancer research right now.
Shares of biotech Nektar Therapeutics lost nearly half their value Monday after the company gave a clinical trial update that fell well short of investor expectations.
Nektar Therapeutics shares plummeted 39% Monday morning after the San Francisco-based biotech company released disappointing clinical trial results over the weekend regarding its key product, NKTR-214. Tests showed that response rates in cancer patients treated with a combination of NKTR-214 and the Bristol-Myers Squibb (BMY) drug Opdivo declined from previous studies. “214 may not be adding an incremental benefit,” wrote Joshua Schimmer of Evercore ISI Research in a note today.
Nektar Therapeutics Inc. shares dropped 35% in Monday morning trade after the company released early data from a phase 1/2 clinical trial testing the company's NKTR-214 in combination with Bristol-Myers Squibb's cancer drug Opdivo. Bristol-Myers shares declined nearly 1% premarket. The trial, which tested the safety and efficacy of the combination in patients with stage IV metastatic melanoma, renal cell carcinoma and urothelial cancers, had "underwhelming" results, said EvercoreISI analyst Josh Schimmer.
Bristol-Myers Squibb Company today announced updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo versus Yervoy in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection.
Bristol-Myers Squibb Company today announced results from a part of the Phase 3 CheckMate -227 trial that evaluated Opdivo plus low-dose Yervoy and Opdivo plus chemotherapy versus chemotherapy in patients with first-line advanced non-small cell lung cancer with PD-L1 expression <1%, across squamous and non-squamous tumor histologies .
Nektar Therapeutics lost a third of its value in Monday trading after response rates in melanoma and kidney cancer patients decreased in a mid-stage trial of the company’s cancer drug in combination with Bristol-Myers Squibb Co.’s Opdivo. “I do think it will improve with time, but it’s hard to not be nervous about that,” said Brad Loncar, founder of Loncar Cancer Immunotherapy exchange-traded fund, which holds Nektar shares. San Francisco-based Nektar sought to assure investors that responses will get better as patients added in the second part of the study stay on the treatment longer.